RVPHW
Income statement / Annual
Last year (2024), Reviva Pharmaceuticals Holdings, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Reviva Pharmaceuticals Holdings, Inc.'s net income was -$29.92 M.
See Reviva Pharmaceuticals Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
02/29/2020 |
02/28/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$724.74 K
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$724.74 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$22.91 M
|
$31.42 M
|
$18.95 M
|
$4.85 M
|
$295.15 K
|
$195.74 K
|
$946.30 K
|
| General & Administrative Expenses |
$0.00
|
$8.08 M
|
$5.36 M
|
$5.25 M
|
$2.14 M
|
$181.12 K
|
$175.58 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.89 M
|
$8.08 M
|
$5.36 M
|
$5.25 M
|
$2.14 M
|
$181.12 K
|
$175.58 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$0.00
|
| Operating Expenses |
$30.80 M
|
$39.50 M
|
$24.31 M
|
$10.10 M
|
$2.43 M
|
$376.86 K
|
$1.12 M
|
| Cost And Expenses |
-$30.80 M
|
$39.50 M
|
$24.31 M
|
$10.10 M
|
$2.43 M
|
$376.86 K
|
$1.12 M
|
| Interest Income |
$361.37 K
|
$0.00
|
$182.80 K
|
$0.00
|
$105.18 K
|
$201.00
|
$0.00
|
| Interest Expense |
$18.50 K
|
$0.00
|
$182.80 K
|
$2.41 K
|
$1.45 M
|
$469.37 K
|
$557.68 K
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$194.71 K
|
$236.56 K
|
$105.77 K
|
$846.00
|
$1.02 K
|
| EBITDA |
-$29.88 M |
-$39.50 M |
-$24.11 M |
-$10.10 M |
-$2.33 M |
-$376.01 K |
-$1.12 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$899.60 K
|
$39.50 M
|
-$11.91 K
|
$1.59 M
|
-$1.35 M
|
-$469.17 K
|
-$557.68 K
|
| Income Before Tax |
-$29.90 M
|
-$39.24 M
|
-$24.32 M
|
-$8.52 M
|
-$3.78 M
|
-$846.03 K
|
-$1.68 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$19.51 K
|
$16.95 K
|
$20.78 K
|
$6.00 K
|
$800.00
|
$800.00
|
$800.00
|
| Net Income |
-$29.92 M
|
-$39.26 M
|
-$24.34 M
|
-$8.52 M
|
-$3.78 M
|
-$846.83 K
|
-$1.68 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.9 |
-1.6497 |
-1.4481 |
-0.5762 |
-1.2357 |
-0.31 |
0.2815 |
| EPS Diluted |
-0.9 |
-1.6497 |
-1.4481 |
-0.5762 |
-1.2357 |
-0.31 |
0.2815 |
| Weighted Average Shares Out |
$33.15 M
|
$23.80 M
|
$19.52 M
|
$14.79 M
|
$3.06 M
|
$2.77 M
|
$2.04 M
|
| Weighted Average Shares Out Diluted |
$33.15 M
|
$23.80 M
|
$19.52 M
|
$14.79 M
|
$3.06 M
|
$2.77 M
|
$2.04 M
|
| Link |
|
|
|
|
|
|
|
